➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKinsey
Merck
McKesson
Express Scripts
Johnson and Johnson

Last Updated: September 21, 2021

DrugPatentWatch Database Preview

Claims for Patent: 9,522,117


Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,522,117
Title:Bromocriptine formulations
Abstract: The present application describes pharmaceutical formulations of bromocriptine mesylate and methods of manufacturing and using such formulations. The formulations are useful for improving glycemic control in the treatment of type 2 diabetes.
Inventor(s): Cincotta; Anthony H. (Tiverton, RI), Bowe; Craig Michael (Encinitas, CA), Stearns; Paul Clark (San Diego, CA), Weston; Laura Jean (Escondido, CA)
Assignee: VeroScience LLC (Tiverton, RI)
Application Number:14/920,123
Patent Claims: 1. A tablet comprising micronized bromocriptine mesylate and one or more excipients; wherein the micronized bromocriptine mesylate is present in an amount that provides a dose of at least about 0.8 mg of bromocriptine per tablet; wherein the micronized bromocriptine mesylate has Dv90 of less than about 10 .mu.m; and wherein the tablet provides a dissolution profile, when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37.degree. C., wherein at least about 90% of the bromocriptine mesylate has been released at about 30 minutes.

2. The tablet according to claim 1, wherein the bromocriptine mesylate is present in an amount that provides a dose of about 0.8 mg of bromocriptine per tablet.

3. The tablet according to claim 1, wherein the bromocriptine mesylate has a particle size distribution with a Dv90 of less than about 5 .mu.m.

4. The tablet according to claim 1, wherein the bromocriptine mesylate has a particle size distribution with a Dv99 of less than about 15 .mu.m.

5. The tablet according to claim 1, wherein the bromocriptine mesylate has a volume-based particle size distribution wherein not more than about 20% of the bromocriptine mesylate has a particle size of less than about 1 .mu.m.

6. The tablet according to claim 1, wherein the tablet provides a dissolution profile, when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37.degree. C., wherein at least about 95% of the bromocriptine mesylate has been released at about 30 minutes.

7. The tablet according to claim 1, wherein the tablet provides a dissolution profile, when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37.degree. C., wherein at least about 90% of the bromocriptine mesylate has been released at about 20 minutes.

8. The tablet according to claim 1, wherein the tablet provides a dissolution profile, when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37.degree. C., wherein not more than about 50% of the bromocriptine mesylate has been released at about 7 minutes and not more than about 75% of the bromocriptine mesylate has been released at about 10 minutes.

9. A method for the manufacture of a bromocriptine mesylate tablet comprising: processing bromocriptine mesylate to reduce the average particle size of the bromocriptine mesylate to provide bromocriptine mesylate that has a Dv90 of less than about 20 .mu.m; blending the processed bromocriptine mesylate with excipients to form a mixture wherein the bromocriptine mesylate is substantially evenly distributed in the mixture, and compressing the mixture to form a tablet; wherein the tablet comprises bromocriptine mesylate in an amount that provides a dose of at least about 0.8 mg of bromocriptine; and wherein the tablet provides a dissolution profile, when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37.degree. C., wherein at least about 90% of the bromocriptine mesylate has been released at about 30 minutes.

10. The method according to claim 9, wherein the bromocriptine mesylate is present in an amount that provides a dose of about 0.8 mg of bromocriptine per tablet.

11. The method according to claim 9, wherein the bromocriptine mesylate has Dv90 of less than about 10 .mu.m after the processing.

12. The method according to claim 9, wherein the bromocriptine mesylate has a Dv90 of less than about 5 .mu.m after the processing.

13. The method according to claim 9, wherein the processing comprises micronizing the bromocriptine mesylate.

14. The method according to claim 9, wherein the tablet provides a dissolution profile, when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37.degree. C., wherein at least about 95% of the bromocriptine mesylate has been released at about 30 minutes.

15. The method according to claim 9, wherein the tablet provides a dissolution profile, when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37.degree. C., wherein at least about 90% of the bromocriptine mesylate has been released at about 20 minutes.

16. The method according to claim 9, wherein the tablet provides a dissolution profile, when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37.degree. C., wherein not more than about 50% of the bromocriptine mesylate has been released at about 7 minutes and not more than about 75% of the bromocriptine mesylate has been released at about 10 minutes.

17. The method according to claim 9, wherein the mixture is transferred from a blending apparatus via a transfer unit to a tableting apparatus for compressing the mixture to form tablets that have a substantially uniform bromocriptine mesylate content.

18. A method for the manufacture of a bromocriptine mesylate tablet comprising: determining that bromocriptine mesylate has a particle size distribution equivalent to a volume-based particle size distribution with a Dv90 of less than about 20 .mu.m; blending the bromocriptine mesylate of determined particle size distribution with excipients to form a mixture wherein the bromocriptine mesylate is substantially evenly distributed in the mixture, and compressing the mixture to form a tablet; wherein the tablet comprises bromocriptine mesylate in an amount that provides a dose of at least about 0.8 mg of bromocriptine; and wherein the tablet provides a dissolution profile, when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37.degree. C., wherein at least about 90% of the bromocriptine mesylate has been released at about 30 minutes.

19. The method of treatment for improving glycemic control in a type 2 diabetes patient comprising administering to the patient a bromocriptine mesylate tablet according to claim 1.

20. A method of treatment for improving glycemic control in a type 2 diabetes patient comprising preparing at least one bromocriptine tablet by a method according to claim 9, and providing the bromocriptine mesylate tablet for administration to the patient.

21. A dosage form comprising bromocriptine mesylate and one or more excipients in the form of a tablet; wherein the dosage form provides for absorption of a substantial amount of bromocriptine through the gastric and/or intestinal mucosa when administered to a subject; wherein the bromocriptine mesylate has a particle size distribution with a span of about 2 or lower; and wherein the dosage form exhibits a pharmacokinetic profile wherein the time to maximum plasma concentration (T.sub.max) of bromocriptine is between about 30 and about 60 minutes following oral administration of the dosage form to the subject under fasting conditions or the T.sub.max of bromocriptine is between about 90 and about 120 minutes following oral administration of the dosage form to the subject under high fat fed conditions.

22. A dosage form comprising bromocriptine in micronized form and one or more excipients; wherein the dosage form is in the form of a tablet; wherein the dosage form provides for absorption of a substantial amount of bromocriptine through the gastric and/or intestinal mucosa when administered orally to a subject; and wherein the dosage form has a dissolution profile wherein at least about 80% of the bromocriptine has been released at about 30 minutes, when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37.degree. C.

23. A dosage form comprising bromocriptine and one or more excipients in the form of a tablet; wherein the dosage form provides for absorption of a substantial amount of bromocriptine through the gastric and/or intestinal mucosa when administered orally to a subject; wherein the bromocriptine has a particle size distribution with a span of about 2 or lower; and wherein the dosage form has a dissolution profile wherein at least about 80% of the bromocriptine has been released at about 30 minutes, when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37.degree. C.

24. The dosage form of claim 23, wherein the bromocriptine is in the form of a salt of bromocriptine.

25. The dosage form of claim 23, wherein the bromocriptine is in the form of bromocriptine mesylate.

26. The dosage form of claim 23, comprising a dose of at least about 0.8 mg of bromocriptine.

27. The dosage form of claim 23, comprising a dose of about 0.8 mg of bromocriptine.

28. The dosage form of claim 23, wherein the bromocriptine has a Dv90 of less than about 20 .mu.m.

29. The dosage form of claim 23, wherein the bromocriptine has a Dv90 of less than about 10 .mu.m.

30. The dosage form of claim 23, wherein the bromocriptine has a Dv99 of less than about 15 .mu.m.

31. The dosage form of claim 23, wherein the bromocriptine has a volume-based particle size distribution wherein not more than about 20% of the bromocriptine has a particle size of less than about 1 .mu.m.

32. The dosage form of claim 23, wherein the bromocriptine is in micronized form.

33. The dosage form of claim 23, wherein the dosage form has a dissolution profile wherein at least about 90% of the bromocriptine has been released at about 30 minutes, when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37.degree. C.

34. The dosage form of claim 23, wherein the dosage form has a dissolution profile wherein not more than about 50% of the bromocriptine has been released at about 7 minutes and not more than about 75% of the bromocriptine has been released at about 10 minutes when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37.degree. C.

35. The dosage form of claim 23, wherein the dosage form exhibits a pharmacokinetic profile wherein the time to maximum plasma concentration (T.sub.max) of bromocriptine is between about 30 and about 60 minutes following oral administration of the dosage form to the subject under fasting conditions or the T.sub.max of bromocriptine is between about 90 and about 120 minutes following oral administration of the dosage form to the subject under high fat fed conditions.

36. A method of improving glycemic control in a type 2 diabetes patient, comprising administering orally to the patient a dosage form according to claim 23.

37. The method of claim 36, wherein the dosage form is administered in the morning within about two hours after waking.

38. A dosage form comprising bromocriptine and one or more excipients in the form of a tablet; wherein the dosage form provides for absorption of a substantial amount of bromocriptine through the gastric and/or intestinal mucosa when administered orally to a subject; wherein the bromocriptine has a Dv90 of less than about 10 .mu.m; and wherein the dosage form has a dissolution profile wherein at least about 80% of the bromocriptine has been released at about 30 minutes, when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37.degree. C.

39. The dosage form of claim 38, wherein the bromocriptine is in the form of a salt of bromocriptine.

40. The dosage form of claim 38, wherein the bromocriptine is in the form of bromocriptine mesylate.

41. The dosage form of claim 38, wherein the bromocriptine has a Dv99 of less than about 15 .mu.m.

42. The dosage form of claim 38, comprising a dose of at least about 0.8 mg of bromocriptine.

43. The dosage form of claim 38, wherein the bromocriptine has a volume-based particle size distribution wherein not more than about 20% of the bromocriptine has a particle size of less than about 1 .mu.m.

44. The dosage form of claim 38, wherein the bromocriptine is in micronized form.

45. The dosage form of claim 38, wherein the dosage form has a dissolution profile wherein at least about 90% of the bromocriptine has been released at about 30 minutes, when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37.degree. C.

46. The dosage form of claim 38, wherein the dosage form has a dissolution profile wherein not more than about 50% of the bromocriptine has been released at about 7 minutes and not more than about 75% of the bromocriptine has been released at about 10 minutes when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37.degree. C.

47. The dosage form of claim 38, wherein the dosage form exhibits a pharmacokinetic profile wherein the time to maximum plasma concentration (T.sub.max) of bromocriptine is between about 30 and about 60 minutes following oral administration of the dosage form to the subject under fasting conditions or the T.sub.max of bromocriptine is between about 90 and about 120 minutes following oral administration of the dosage form to the subject under high fat fed conditions.

48. A method of improving glycemic control in a type 2 diabetes patient, comprising administering orally to the patient a dosage form according to claim 38.

49. The method of claim 48, wherein the dosage form is administered in the morning within about two hours after waking.

50. A dosage form comprising bromocriptine and one or more excipients in the form of a tablet; wherein the dosage form provides for absorption of a substantial amount of bromocriptine through the gastric and/or intestinal mucosa when administered orally to a subject; wherein the bromocriptine has a Dv99 of less than about 15 .mu.M; and wherein the dosage form has a dissolution profile wherein at least about 80% of the bromocriptine has been released at about 30 minutes, when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37.degree. C.

51. A dosage form comprising: micronized bromocriptine mesylate and one or more excipients in the form of a tablet; wherein the micronized bromocriptine mesylate has a Dv90 of less than about 10 .mu.m, and wherein not more than about 20% of the bromocriptine mesylate has a particle size of less than about 1 .mu.m; and wherein the dosage form provides a dissolution profile, when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37.degree. C., wherein not more than about 50% of the bromocriptine mesylate has been released at about 7 minutes, not more than about 75% of the bromocriptine mesylate has been released at about 10 minutes, and at least about 80% of the bromocriptine mesylate has been released at about 30 minutes.

52. The dosage form of claim 51, wherein the bromocriptine mesylate has a Dv99 of less than about 15 .mu.m.

53. The dosage form of claim 51, wherein the bromocriptine mesylate has a volume-based particle size distribution with a span of about 2 or lower.

54. The dosage form of claim 51, wherein the dosage form provides a dissolution profile, when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37.degree. C., wherein at least about 90% of the bromocriptine mesylate has been released at about 30 minutes.

55. A method of improving glycemic control in a type 2 diabetes patient, comprising administering orally to the patient a dosage form according to claim 51.

56. The method of claim 55, wherein the dosage form is administered in the morning within about two hours after waking.

57. A dosage form comprising: micronized bromocriptine mesylate and one or more excipients in the form of a tablet; wherein the micronized bromocriptine mesylate has a Dv90 of less than about 10 .mu.m, and a volume-based particle size distribution with a span of about 2 or lower; and wherein the dosage form provides a dissolution profile, when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37.degree. C., wherein at least about 80% of the bromocriptine mesylate has been released at about 30 minutes.

58. The dosage form of claim 57, wherein the bromocriptine mesylate has a Dv99 of less than about 15 .mu.m.

59. The dosage form of claim 57, wherein the dosage form provides a dissolution profile, when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37.degree. C., wherein at least about 90% of the bromocriptine mesylate has been released at about 30 minutes.

60. A method of improving glycemic control in a type 2 diabetes patient, comprising administering orally to the patient a dosage form according to claim 57.

61. The method of claim 60, wherein the dosage form is administered in the morning within about two hours after waking.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Express Scripts
Colorcon
AstraZeneca
Medtronic
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.